4-Bromo-L-β-homophenylalanine hydrochloride
Need Assistance?
  • US & Canada:
    +
  • UK: +

4-Bromo-L-β-homophenylalanine hydrochloride

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
β−Amino acids
Catalog number
BAT-006816
CAS number
331763-71-4
Molecular Formula
C10H13BrClNO2
Molecular Weight
294.57
4-Bromo-L-β-homophenylalanine hydrochloride
IUPAC Name
(3S)-3-amino-4-(4-bromophenyl)butanoic acid;hydrochloride
Synonyms
H-Phe(4-Br)-(C#CH2)OH HCl; (S)-3-Amino-4-(4-bromophenyl)butanoic acid hydrochloride
Related CAS
270062-84-5 (free base)
Purity
95%
Storage
Store at 2-8 °C
InChI
InChI=1S/C10H12BrNO2.ClH/c11-8-3-1-7(2-4-8)5-9(12)6-10(13)14;/h1-4,9H,5-6,12H2,(H,13,14);1H/t9-;/m0./s1
InChI Key
QMUGXLUXLGZZSC-FVGYRXGTSA-N
Canonical SMILES
C1=CC(=CC=C1CC(CC(=O)O)N)Br.Cl
1.The Effect of Systemic Tamsulosin Hydrochloride on Choroidal Thickness Measured by Enhanced Depth Imaging Spectral Domain Optical Coherence Tomography.
Sari E1, Sari ES2, Yazici A2, Koç A1, Bulbul E3, Koytak A4, Ermis SS2, Erol MK5. Curr Eye Res. 2015;40(10):1068-72. doi: 10.3109/02713683.2014.971935. Epub 2014 Dec 12.
BACKGROUND: To evaluate the effects of selective α1A-adrenoceptor antagonist tamsulosin hydrochloride on choroidal thickness using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT).
2.Inhibition of local blood flow control systems in the mammary glands of lactating cows affects uptakes of energy metabolites from blood.
Madsen TG1, Cieslar SR2, Trout DR3, Nielsen MO1, Cant JP4. J Dairy Sci. 2015 May;98(5):3046-58. doi: 10.3168/jds.2014-8200. Epub 2015 Mar 6.
To test the effect of mammary blood flow on net uptakes of milk precursors by the mammary glands, inhibitors of nitric oxide synthase (NOS) and cyclooxygenase (COX) were infused into the mammary circulation of 4 lactating cows. Inhibitors were infused in a 4×4 Latin square design, where treatments were infusion for 1 h of saline, NOS inhibitor (Nω-nitro-l-arginine methyl ester hydrochloride), COX inhibitor (indomethacin), or both NOS + COX inhibitors into one external iliac artery. Para-aminohippuric acid was also infused to allow for estimation of iliac plasma flow (IPF), of which approximately 80% flows to the mammary glands. Blood samples were collected before, during, and after inhibitor infusion from the contralateral external iliac artery and ipsilateral mammary vein. Inhibition of COX and NOS each produced a decrease in IPF, although the NOS effect was smaller and IPF continued to be depressed throughout the recovery period. The combination of COX and NOS inhibition produced a 50% depression in IPF and there was no carryover into the recovery period.
3.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Lee JG1, Wu R2. Neoplasia. 2015 Feb;17(2):190-200. doi: 10.1016/j.neo.2014.12.008.
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular due to the anticipation that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients for specific mutations in light of attempting to administer specific anticancer agents that are most effective. In this study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC in vitro and in vivo. In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. In xenograft models, combination treatment also demonstrated greater inhibition of tumor growth compared to individual treatment. The anti-tumor effect observed was secondary to the targeting of angiogenesis, evidenced by decreased vascular endothelial growth factor (VEGF) levels and decreased levels of CD31 and microvessel density.
4.Oral exposure to the anti-pyridoxine compound 1-amino D-proline further perturbs homocysteine metabolism through the transsulfuration pathway in moderately vitamin B₆ deficient rats.
Mayengbam S1, Raposo S1, Aliani M1, House JD2. J Nutr Biochem. 2015 Mar;26(3):241-9. doi: 10.1016/j.jnutbio.2014.10.014. Epub 2014 Dec 3.
Pyridoxal 5'-phosphate (PLP; a B₆ vitamer) serves as an important cofactor in a myriad of metabolic reactions, including the transsulfuration (TS) pathway, which converts homocysteine (Hcy) to cysteine. While overt vitamin B₆ deficiency is rare, moderate deficiency is common and may be exacerbated by anti-pyridoxine factors in the food supply. To this end, we developed a model of moderate B₆ deficiency and a study was conducted to examine the in vivo effect of 1-amino D-proline (1ADP), an anti-pyridoxine factor found in flaxseed, on indices of Hcy metabolism through the TS pathway in moderately B₆ deficient rats. Male weaning rats received a semi-purified diet containing either 7 mg/kg (control; CD) or 0.7 mg/kg (moderately deficient; MD) diet of pyridoxine·hydrochloride (PN∙HCl), each with 1 of 4 levels of 1ADP, viz. 0, 0.1, 1 and 10 mg/kg diet for 5 weeks. Perturbations in vitamin B₆ biomarkers were more pronounced in the MD group. Plasma PLP was significantly reduced, while plasma Hcy (8-fold) and cystathionine (11-fold) were increased in rats consuming the highest amount of 1ADP in the MD group.
Online Inquiry
Verification code
Inquiry Basket